Investor Relations

Investor Relations

CORPORATE PROFILE

We are a clinical late-stage pharmaceutical company focused on the development and commercialization of first-in-class pharmaceutical therapies for the treatment of ocular blinding diseases. Our product candidates are based on TRS, a New Chemical Entity, which is a potent local immunomodulatory agent. TRS is being developed as an eye drop formulation, TRS01, to treat the signs and symptoms of active uveitis in patients with uveitic glaucoma. TRS01 is currently being investigated in a phase-3 trial. The company is also developing TRS02, a slow-release formulation of the same compound, to be administered as intravitreal injections for the treatment of various back-of-the-eye inflammatory indications.

NEWS

26 June, 2022

Tarsier® Pharma receives certificate of registration for trademark Tarsier® in the US & other territories

Read More →

21 March, 2022

Bridging the Gender Gap in Scientific Innovation: Tarsier’s CEO, Dr. Daphne Haim-Langford, is interviewed in Oppenheimer’s “Let’s Talk Future™” podcast about women in scientific innovation

Read More →

March 3, 2022

Dr. Daphne Haim-Langford will participate as keynote speaker at the Israeli Society for Vision and Eye Research (ISVER) Annual Meeting

Read More →

March 01, 2022

Tarsier Pharma Adds Ocular Immunology Experts to Scientific Advisory Board

Read More →

Feb 08, 2022

Dr. Daphne Haim-Langford presents Tarsier’s progress to the European Parliament

Read More →

January 05, 2022

Tarsier Pharma is launching a dedicated website about uveitic glaucoma

Read More →

December 2, 2021

Tarsier Pharma Announces two presentations at the International Ocular Inflammation Society (IOIS) 2021 Congress

Read More →

30 November 2021

Tarsier’s CEO and Founder, Dr. Daphne Haim Langford, wins the 2021 EU Prize for Women Innovators

Read More →

November 8, 2021

TRS01 Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual meeting

Read More →

September 22, 2021

First Patient Randomized in TRS4VISION Phase-III Clinical Trial in Patients with Active Non-Infectious Anterior Uveitis Including Patients with Uveitic Glaucoma

Read More →

August 24, 2021

Tarsier Pharma Raises Capital to Execute Phase-3 Clinical Trial

Read More →

July 28, 2021

Tarsier Pharma, in Collaboration with Uveitis Experts, Published a Research Article about a New Grading Image Scale for Assessing Uveitis

Read More →

April 26, 2021

Tarsier Pharma Completes Successful Pre-IND Meeting with the FDA for its TRS02 Program of Back-of-the-Eye Blinding Indications

Read More →

15 March, 2021

Tarsier Pharma Expands Executive Leadership Team

Read More →

22 December, 2020

Tarsius Pharma Announces Company Name Change to Tarsier Pharma

Read More →

17 October, 2020

Tarsier Pharma’s Positive End-Of-Phase 2 Meeting With The U.S. FDA Sets Stage For TRS01 Phase III Program In Uveitis

Read More →

October 5, 2020

Tarsius Pharma Achieves Positive Results in Proof of Concept Study for TRS01 Targeting Uveitis

Read More →

June 22, 2020

Tarsius Pharma Completes Patient Enrollment In Clinical Trial Of TRS01 In Patients With Non-Infectious Uveitis

Read More →

Feb. 25, 2020

Dosing of first patient in Tarsius 2020 Phase I/IIa Clinical Study of TRS01

Read More →

Feb. 04, 2020

Dosing Of First Patient In GADOT 20/20 Trial, A Phase I/IIa Study Of TRS01 In Patients With Non-Infectious Anterior Uveitis

Read More →

Nov. 19, 2019

Tarsius Pharma Announces Granting Of Orphan Drug Designation For TRS By The European Medicines Agency

Read More →

Oct. 6, 2019

BioLight’s New Investment In Tarsius Pharma Ltd. That Develops A Novel Platform For The Treatment Of Blinding Ocular Diseases

Read More →

Sept. 24, 2019

Tarsius Pharma Announces FDA Acceptance Of IND Application For TRS01

Read More →

Sept. 16, 2019

Tarsius Pharma Awarded €2.4 Million EU Grant To Support First-In-Human Clinical Trial For TRS01

Read More →

EVENTS

08 June, 2022

Virtual Panel Of Cantor And Fitzgerald Will Discuss Market Opportunities In Ophthalmic Indications, Hosting Tarsier Pharma

Read More →

April 11-14, 2022

Tarsier Pharma Will Participate at the 21st Annual Needham Virtual Healthcare Conference

Read More →

March 15-17, 2022

Tarsier Pharma Will Participate At The Oppenheimer 32nd Virtual Annual Healthcare Conference

Read More →

February 27-March 2, 2022

TRS01 potential presented at the American-European-Congress-of-Ophthalmic-Surgery by Dr. Raizman

Read More →

January 10-13, 2022

Tarsier Pharma Will Participate At The H.C. Wainwright Bioconnect Conference

Read More →

December 7, 2021

Tarsier Pharma will participate at UBS Ophthalmology Day

Read More →

November 15, 2021

Tarsier Pharma Will Participate At The H.C. Wainwright 7th Annual Israel Virtual Conference

Read More →

19-20 October, 2021

Tarsier Pharma Will Participate At The Needham Virtual Biotech Private Company 1×1 Forum

Read More →

October 07, 2021

Tarsier Pharma Will Present At The Ophthalmology Futures European Forum

Read More →

September 13-15, 2021

Tarsier Pharma Will Participate at the H.C. Wainwright 23rd Annual Global Investment Conference

Read More →

September 9-10, 2021

Tarsier Pharma Will Participate at the 2021 Wells Fargo Virtual Healthcare Conference

Read More →

August 17, 2021

Tarsier Pharma Will Participate at the H.C. Wainwright Ophthalmology
Virtual Conference

Read More →

June 10, 2021

Dr. Daphne Haim-Langford Will Co-Chair OIS@Israel

Read More →

21 May, 2021

Tarsier Pharma Will Participate In The Oppenheimer Rare & Orphan Disease Summit

Read More →

12-15 April, 2021

Tarsier Pharma Will Present in the 20th Annual Needham Virtual Healthcare Conference

Read More →

08 April, 2021

Tarsier Pharma Will Present in the Anterior Innovation Showcase of the Ophthalmology Innovation Summit (OIS)

Read More →

16-18 March, 2021

Tarsier Pharma Will Participate in the Oppenheimer 31st Virtual Annual Healthcare Conference

Read More →

19 February, 2021

Virtual panel of Cantor and Fitzgerald will discuss market opportunities in ophthalmic indications, hosting Tarsier Pharma

Read More →

6-13 January, 2021

Tarsier Pharma’s to Participate at the LifeSci Partners 10th Annual Healthcare Corporate Access Event in Early January 2021

Read More →

12 December, 2020

Tarsius Pharma will present at the 4th Annual Sonoma Eye Conference results of its Phase I/II trial of TRS01 targeting Uveitis

Read More →

30 November, 2020

Tarsius Pharma will Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Read More →

November 6, 2020

Join us at the KOL Webinar on Blinding Ocular Inflammatory Diseases

Read More →

May 3-7, 2020

Meet us at ARVO 2020 in Baltimore

Read More →

June 15, 2020

Dr. Daphne Haim-Langford will co-chair OIS@Israel

Read More →

January 13-16, 2020

Tarsius Pharma @ JPM 2020

Read More →

November 13-16, 2019

Tarsius’ Founder & CEO Will Present As Invited Speaker @ The 15th International Ocular Inflammation Society (IOIS) 2019

Read More →
Scroll to Top Skip to content